PMV Pharmaceuticals, Inc.

PMV Pharmaceuticals, Inc. is a company founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D. and Thomas Shenk, Ph.D. It describes itself as building a precision oncology platform that leverages more than four decades of research experience and unique insights into the p53 protein, aiming to selectively target mutant p53 and provide therapies for patients whose tumors harbor these gene mutations. Its pipeline includes rezatapopt, and it has announced public offerings of securities.

PMV Pharmaceuticals was founded in 2013 by David Mack, Ph.D., Arnold Levine, Ph.D. and Thomas Shenk, Ph.D. The company states that over the past ten years it has built a precision oncology platform that leverages more than four decades of research experience and unique insights into the p53 protein. It has assembled a management team of biopharmaceutical experts with extensive experience in oncology drug discovery and development. Its pipeline includes rezatapopt, and it has announced public offerings of securities.

Precision oncology platform selectively targeting mutant p53

• rezatapopt

  Listed in the PMV Pipeline.

1. 1PMV Pharma | Harnessing the Power of p53 to treat Cancerpmvpharma.com
2. 2Management | Harnessing the Power of p53 to treat Cancer | PMV Pharmapmvpharma.com
3. 3Science | Harnessing the Power of p53 to Treat Cancer | PMV Pharmapmvpharma.com
4. 4PMV Pharma Prices IPO At $18/Shr, At High End Of Rangefinanznachrichten.de
5. 5PMV Pharma Secures $62 Million in Series C Financing To Develop Cancer Drugs Targeting p53prweb.com